Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response
…, H Dong, Y Zhao, GC Karakousis, TC Mitchell… - Nature, 2018 - nature.com
Tumour cells evade immune surveillance by upregulating the surface expression of programmed
death-ligand 1 (PD-L1), which interacts with programmed death-1 (PD-1) receptor on T …
death-ligand 1 (PD-L1), which interacts with programmed death-1 (PD-1) receptor on T …
TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion
…, RK Amaravadi, X Xu, GC Karakousis, TC Mitchell… - Nature, 2019 - nature.com
Exhausted CD8 + T (T ex ) cells in chronic infections and cancer have limited effector
function, high co-expression of inhibitory receptors and extensive transcriptional changes …
function, high co-expression of inhibitory receptors and extensive transcriptional changes …
[PDF][PDF] Developmental relationships of four exhausted CD8+ T cell subsets reveals underlying transcriptional and epigenetic landscape control mechanisms
…, RK Amaravadi, X Xu, GC Karakousis, TC Mitchell… - Immunity, 2020 - cell.com
CD8 + T cell exhaustion is a major barrier to current anti-cancer immunotherapies. Despite
this, the developmental biology of exhausted CD8 + T cells (Tex) remains poorly defined, …
this, the developmental biology of exhausted CD8 + T cells (Tex) remains poorly defined, …
[PDF][PDF] Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma
…, K Skalla, MB Whedon, S Bivens, T Mitchell… - Journal of Clinical …, 2002 - Citeseer
Purpose: The primary purpose of this study was to compare the neuropsychologic functioning
of long-term survivors of breast cancer and lymphoma who had been treated with standard-…
of long-term survivors of breast cancer and lymphoma who had been treated with standard-…
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3 …
…, J Maleski, M Jones, SJ Diede, TC Mitchell - The Lancet …, 2019 - thelancet.com
Background Immunotherapy combination treatments can improve patient outcomes. Epacadostat,
an IDO1 selective inhibitor, and pembrolizumab, a PD-1 inhibitor, showed promising …
an IDO1 selective inhibitor, and pembrolizumab, a PD-1 inhibitor, showed promising …
A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma
…, MD Farwell, GC Karakousis, EJ Wherry, TC Mitchell - Nature medicine, 2019 - nature.com
Immunologic responses to anti-PD-1 therapy in melanoma patients occur rapidly with
pharmacodynamic T cell responses detectable in blood by 3 weeks. It is unclear, however, …
pharmacodynamic T cell responses detectable in blood by 3 weeks. It is unclear, however, …
Racial bias in mock juror decision-making: A meta-analytic review of defendant treatment
TL Mitchell, RM Haw, JE Pfeifer, CA Meissner - Law and human behavior, 2005 - Springer
Common wisdom seems to suggest that racial bias, defined as disparate treatment of
minority defendants, exists in jury decision-making, with Black defendants being treated more …
minority defendants, exists in jury decision-making, with Black defendants being treated more …
Shared and distinct biological circuits in effector, memory and exhausted CD8+ T cells revealed by temporal single-cell transcriptomics and epigenetics
…, PK Yan, GC Karakousis, X Xu, TC Mitchell… - Nature …, 2022 - nature.com
Naïve CD8 + T cells can differentiate into effector (T eff ), memory (T mem ) or exhausted (T
ex ) T cells. These developmental pathways are associated with distinct transcriptional and …
ex ) T cells. These developmental pathways are associated with distinct transcriptional and …
[HTML][HTML] Epacadostat plus pembrolizumab in patients with advanced solid tumors: phase I results from a multicenter, open-label phase I/II trial (ECHO-202/KEYNOTE …
TC Mitchell, O Hamid, DC Smith, TM Bauer… - Journal of Clinical …, 2018 - ncbi.nlm.nih.gov
Purpose Tumors may evade immunosurveillance through upregulation of the indoleamine 2,
3-dioxygenase 1 (IDO1) enzyme. Epacadostat is a potent and highly selective IDO1 …
3-dioxygenase 1 (IDO1) enzyme. Epacadostat is a potent and highly selective IDO1 …
Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)
…, ACJ Van Akkooi, MA Davies, TC Mitchell… - Nature medicine, 2021 - nature.com
The association among pathological response, recurrence-free survival (RFS) and overall
survival (OS) with neoadjuvant therapy in melanoma remains unclear. In this study, we pooled …
survival (OS) with neoadjuvant therapy in melanoma remains unclear. In this study, we pooled …